ClinicalTrials.gg
CompletedNCT06637514Updated May 13, 2026

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

A Phase 2 interventional study of JNT-517 Tablet and Placebo in Phenylketonuria (PKU), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 7 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Enrollment
44th of 63
14 · median 33
Started
2025
with 5 others
Phase 2
13 of 93
1 open now
Registered
85th of 93
by date
Lead sponsor
5 of 93
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 44th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 13 in phase 2, and was the 85th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety.

Participants will:

  • Take 75 mg JNT-517 or a placebo BID (2x per day) for 28 days
  • Visit the clinic or have a mobile health nurse visit your home for checkups and tests
  • Collect urine sample at home and bring to clinic on specified days
  • Keep a food diary 3 days before each study visit
03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • PKU
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males and females 12 to less than 18 years of age, inclusive on Day 1.
  2. Clinical diagnosis of PKU.
  3. Ability to swallow tablets.
  4. Average of 2 plasma Phe levels during the Screening period greater than 360 μM and no plasma Phe level less than 300 μM.
  5. Body weight equal or greater than 45 kg and less than 40 kg/m2.
  6. Females of must practice sexual abstinence or agree to use 2 highly effective methods.
  7. Capable of giving signed (emancipated minors) or parent/legal guardian to provide informed consent and the participant to give assent and confirm ability to comply with study procedures.

Key Exclusion Criteria:

  1. Any acute or chronic medical condition that would prevent the participant from complying with the procedures or place the participant at risk if they participate in the study.
  2. Positive for or C or .
  3. Any history of in the last 5 years, excluding nonmelanoma skin cancer.
  4. Any history of liver disease.
  5. Any history of cataracts or more than minimal cataracts observed during the Screening ophthalmologic examination.
  6. Any surgical or medical conditions that may affect study drug absorption, distribution, metabolism, or excretion.
  7. less than 90 mL/min by Cockcroft-Gault formula.
  8. History of drug or alcohol abuse in the last year
  9. Current, recent, or suspected infection within 14 days of Screening of SARS CoV 2/COVID 19.
  10. Participation in another drug trial within 30 days or, if known 5 half-lives of investigational drug (whichever is longer).
  11. Unable to tolerate oral medication.
  12. Allergy to JNT-517 or any component of the investigational product.
  13. Received greater than 50 mL of blood or plasma within 30 days of Screening or greater than 500 mL of blood or plasma within 60 days of Screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    JNT-517 - 75 mg BID

    Drug: JNT-517 Tablet

    Drug: JNT-517 Tablet

  • Placebo comparator
    Placebo - BID

    Drug: Placebo Tablet

    Other: Placebo

  • Experimental
    JNT-517 - 150 mg BID

    Drug: JNT-517 Tablet - 150 mg BID is a potential dose that may be used in the study. After safety, efficacy and pharmacokinetic data (PK) data have been reviewed for the first 5 participants assigned in the study, a decision will be made to increase dosage for additional participants.

    Drug: JNT-517 Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Reported based on results of 12-lead electrocardiograms (ECGs), vital signs and clinical laboratory tests.

    Time frame: Screening to Study Completion (Average of 9 weeks)

Secondary outcomes

  1. Plasma AUC (area under the concentration-time curve)

    Time frame: Screening to Study Completion (Average of 9 weeks)

  2. Cmax (maximum observed concentration)

    Time frame: Screening to Study Completion (Average of 9 weeks)

  3. Tmax (time to Cmax)

    Time frame: Screening to Study Completion (Average of 9 weeks)

  4. Change over time in plasma phenylalanine (Phe) and other amino acids

    Time frame: Screening to Study Completion (Average of 9 weeks)

  5. Change over time in urinary phenylalanine (Phe) and other amino acids

    Time frame: Screening to Study Completion (Average of 9 weeks)

Other outcomes

  1. Plasma metabolites of JNT-517

    Time frame: Screening to Study Completion (Average of 9 weeks)

07

Study locations

7 sites
  • University of Florida (UF) Health Shands Hospital
    Gainesville, Florida 32608, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • University of Texas Health (UTHealth) Science Center at Houston
    Houston, Texas 77030, United States
  • Utah Health - The University of Utah Hospital
    Salt Lake City, Utah 84112, United States
  • Murdoch Children's Research Institute
    Parkville, Melbourne, Victoria 3052, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in May 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 15, 2024
StartActual
Jul 16, 2025
Primary completionActual
May 8, 2026
CompletionActual
May 8, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06637514
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jul 16, 2025
Primary completion
May 8, 2026
Completion
May 8, 2026
Last update
May 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repinatrabit

Start the discussion